

Incidence and Risk Factors for AKI in Preterm Infants Treated with Vancomycin

Seongjae Han, Baek Sup Shin, Hee Gyung Kang
Seoul National University Children's Hospital

Abstract


We analyzed electrical medical record of 320 pediatric patients with venous pH below 7.25 who visited a pediatric emergency room (PER) of a tertiary hospital in South Korea. We found a high incidence of acute kidney injury (AKI) among acidotic patients, and those with metabolic acidosis and especially high anion gap metabolic acidosis were at a higher risk of AKI.

Introduction

- Vancomycin (VCM) is one of the known causes of AKI, which can be life-threatening in preterm infants.
- Perinatal characteristics, such as gestational age or birthweight, and neonatal morbidities, including patent ductus arteriosus or necrotizing enterocolitis (NEC), may contribute to VCM-induced AKI.
- Recent studies have suggested that piperacillin-tazobactam (TZP) may aggravate VCM-induced nephrotoxicity in adults and adolescents.
- This study explored the factors, including the concomitant use of TZP, associated with VCM-induced AKI in preterm infants.

Methods and Materials

- Retrospective single-center study
 - Preterm infants with birth weight < 1,500g
 - Who were born between 2018 and 2021 in a tertiary center
 - Who received VCM for a minimum of 3 days
- AKI defined as a minimum increase in serum creatinine (sCr) of 0.3 mg/dL, and an increase in sCr of at least 1.5 times the baseline level during VCM use and up to 1 week following VCM discontinuation



Patient Characteristics (n=53)

	AKI (n=10)	AKI (n=43)	P value
Gestational age, week	24.0 [24.0-25.0]	26.0 [24.0-28.0]	0.068
Birth weight, g	675 [670-866]	770 [600-955]	0.802
Oligohydramnios	1 (14.3)	6 (15.0)	1.000
Male	7 (70.0)	16 (57.1)	0.552
IUGR	7 (10.0)	10 (23.3)	0.618
Apgar score, 1 min	3.0 ± 1.6	3.6 ± 2.0	0.412
Apgar score, 5 min	6.0 ± 1.9	6.3 ± 2.3	0.745

Results

1. AKI occurred in 10 (18.9%) at 7 days (3 to 11 days) after starting VCM.
2. Gestational age at birth, birth weight, pathogen-proven sepsis, duration of VCM, postmenstrual age at starting VCM, highest concentration of VCM, patent ductus arteriosus at starting VCM, and co-administration of TZP were not statistically different between the AKI & the non-AKI groups.
3. A history of NEC was significantly high in the AKI group (5 (50.0%) vs 2 (4.7%), OR 20.05 [3.11-134.94], p-value 0.002).
4. In multivariable logistic regression, gestational age at birth was significantly differed between the AKI & the non-AKI group.
5. Backward stepwise regression showed that AKI was associated with low gestational age (adjusted OR: 0.58, 95% CI: 0.35-0.98) and a history of NEC (37.65, 3.08-459.96).

Neonatal morbidity and vancomycin related factors

	AKI (n=10)	AKI (n=43)	Univariate OR (95% CI)	P
Sepsis (pathogen (+))	5 (50.0)	16 (37.2)	1.69 (0.42-6.74)	
Duration of VCM (d)	5.0 [3.0-9.0]	4.0 [2.0-9.0]	1.02 (0.94-1.10)	0.701
PMA at VCM, week	27.8 [25.1-40.4]	33.0 [29.2-38.7]	0.96 (0.87-1.05)	0.356
Highest conc. of VCM (µg/mL)	38.5 [29.8-60.5]	36.2 [25.1-44.1]	1.04 (0.99-1.10)	0.088
PDA at starting VCM	7 (70.0)	18 (41.9)	3.24 (0.74-14.26)	0.12
Co-Mx of TZP	4 (40.0)	21 (48.8)	0.70 (0.17-2.83)	0.615
NEC	5 (50.0)	2 (4.7)	20.05 (3.11-135)	0.002

VCM, vancomycin; PMA, postmenstrual age; PDA, patent ductus arteriosus; TZP, piperacillin-tazobactam; NEC, necrotizing enterocolitis; AKI, acute kidney injury; OR, odds ratio; CI, confidence interval.

Multivariable analyses for AKI

	AKI (n=10)	AKI (n=43)	§Multivariate OR (95% CI)	P
Gestational age, week	24.6 [24.3-25.6]	26.4 [24.4-28.4]	0.58 (0.35-0.98)	0.042
PDA at starting VCM	7 (70.0)	18 (41.9)	5.23 (0.67-41.05)	0.115
NEC	5 (50.0)	2 (4.7)	37.65 (3.08-459.96)	0.005

Data are presented as median [interquartile range], or n (%). PDA, patent ductus arteriosus; NEC, necrotizing enterocolitis; AKI, acute kidney injury. §Adjusted for gestational age and PDA at initiation of VCM and NEC.

Conclusions

In very-low birthweight infants, a lower gestational age and history of necrotizing enterocolitis, but not concomitant use of piperacillin-tazobactam, were associated with VCM-induced AKI.

